REFERENCES
- Castiblanco C, Foster CS. Review of systemic immunosuppression for autoimmune uveitis. Ophthalmic Ther. 2014;3:17–36.
- Vitale AT, Foster CS. Treatment of uveitis – Overview. Diagnosis and treatment of uveitis. Philadelphia, PA: WB Saunders; 2002:141.
- Jones NP. Manchester Uveitis Clinic: the first 3000 patients: 2. Complications and management. Ocul Immunol Inflamm. 2015;23:127–134.
- Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013; 52:53–61.
- Avery RK, Michaela MG, and AST Infectious Diseases Community of Practice. Strategies for safe living after solid organ transplantation. Am J Transplant. 2013;13:304–310.
- Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979–995.
- Hornbeak DM, Kempen JH. Safety of immunosuppressive therapy for eye diseases. Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders. Berlin, Springer. 2014; 232–243.
- Doycheva D, Zierhut M, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefe’s Arch Clin and Exp Ophthalmol. 2011;249:1235–1243.
- Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet’s disease. Arthritis Care & Res. 2010;62:1733–1738.
- Matthews J, Matthews D, Jones NP. Long-term ciclosporin for sight-threatening uveitis: efficacy and tolerability. Indian J Ophthalmol. 2010;58:55–58.
- Menezo V, Lau C, Comer M, et al. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Exp Ophthalmol. 2005;33:16–21.
- Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet’s disease: An open-label trial. Arthritis Rheum. 2005;52:2478–2484.
- Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: The Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2011;118:1916–1926.
- Glück T, Kiefmann B, Grohmann M, et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol. 2005;32:1473–1480.
- Merayo-Chalico D, Gómez-Martín A, Piñeirúa-Menéndez K, et al. Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case–control study. Quarterly J Med. 2013;106:451–457.
- Al-Rifai A, Prasad N, Shuttleworth E, et al. Azathioprine-associated lymphopenia in IBD – are our patients in danger? A prospective multi-centre study. J Crohns Colitis. 2009;3:51.
- Liang RH, Yung RW, Chan TK, et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990;34:215–218.
- Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–874.
- Markwart R, Condotta S, Requardt RP, et al. Immunosuppression after sepsis: systemic inflammation and sepsis induce a loss of naïve T-cells but no enduring cell-autonomous defects in T-cell function. PLoS ONE. 2014;9:e115094.